Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary suggests a mix of positive and neutral aspects. Positive factors include strong financial performance and strategic focus on profitable segments like global medical cannabis. However, uncertainties such as the exit from plant propagation, lack of specific timelines, and unclear management responses regarding revenue deceleration create a balanced outlook. The Q&A section did not reveal significant risks but highlighted strategic shifts and market exploration. Overall, the sentiment appears neutral due to the balanced nature of positive growth strategies and uncertainties in execution and market conditions.
Key Financial Performance
Net Revenue $94.2 million, a 7% growth year-over-year. This was supported by record contributions from global Medical Cannabis and Plant Propagation segments.
Global Medical Cannabis Revenue $76.2 million, a 12% increase year-over-year, including 17% growth internationally. This was driven by increased distribution in Germany and new product offerings in Poland.
Consumer Cannabis Net Revenue $5.2 million, down 48% from $9.9 million year-over-year. The decline was due to the strategic shift to focus on portfolio optimization and allocation of cannabis flower to higher-margin business segments.
Plant Propagation Net Revenue $11.3 million, up 27% from $8.9 million year-over-year. However, adjusted gross margin for plant propagation fell to 16% from 40% due to increased contract labor and utilities costs, as well as inventory write-offs of $1.1 million.
Adjusted Gross Margin 62%, a 100 basis points increase year-over-year. This was supported by strong medical cannabis margins of 69%, driven by high-margin international markets and operational efficiencies.
Adjusted EBITDA $18.5 million, slightly down from $19.4 million year-over-year. The decrease was primarily due to lower adjusted gross profit in the Plant Propagation segment and an increase in adjusted SG&A.
Adjusted Net Income $7.2 million, relatively consistent with $7.4 million in the prior year.
Free Cash Flow $15.5 million, down from $27.4 million year-over-year. The decline was due to a decrease in the working capital recovery of $9.2 million.
Cash and Cash Equivalents $154 million, with no cannabis business-related debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New medical cannabis brand in Germany: Introduced a new brand prioritizing affordability while maintaining quality standards.
New proprietary cultivar in Poland: Launched a third proprietary cultivar following success in other markets.
Global medical cannabis revenue growth: Achieved 12% growth in global medical cannabis revenue, with 17% growth internationally.
Germany market expansion: Gained market share in Germany, driven by increased imports and product offerings.
Australia market strategy: Shifting sales mix towards core and premium products to improve margins.
Poland market leadership: Maintained #1 position and expanded product portfolio.
Operational efficiencies in manufacturing: Doubling production at German site and achieving GMP certification for facilities.
Cost reductions and yield improvements: Achieved lower manufacturing costs through higher yields and potency improvements.
Exit from lower-margin Canadian consumer cannabis: Exiting select markets to focus on higher-margin global medical cannabis business.
Divestment of plant propagation operations: Selling controlling stake in Bevo to allocate capital more effectively.
New at-the-market equity program: Established a program to issue and sell up to USD 100 million of common shares for strategic purposes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Exiting Select Canadian Consumer Cannabis Markets: The company plans to exit certain lower-margin Canadian consumer cannabis markets to prioritize higher-margin global medical cannabis business. This could lead to one-time costs impacting cash flow in fiscal Q4.
Divestment of Plant Propagation Business: Aurora is selling its controlling stake in Bevo, its plant propagation business, due to lower margins. This could result in operational disruptions and near-term financial impacts.
Increased Competition in Germany: The German medical cannabis market is experiencing price pressures in the value segment due to new entrants, which could impact Aurora's market share and profitability.
Regulatory Uncertainty in Germany: Potential changes to the telehealth framework and cannabis descheduling in Germany could affect patient access and market dynamics, requiring Aurora to adapt its operations.
Australian Market Transition: Aurora is shifting its Australian sales mix from value-priced products to higher-margin core and premium offerings. This transition may cause near-term pressure on sales and gross profit.
UK Market Challenges: An influx of value products in the UK market has led to lower year-over-year sales, particularly in the premium and super-premium segments where Aurora operates.
Increased SG&A Costs: Higher professional fees, additional headcount, and contract labor costs in Europe and Australia have increased SG&A expenses, potentially impacting profitability.
Plant Propagation Margin Decline: Margins in the plant propagation segment have fallen due to increased labor and utility costs, as well as inventory write-offs, which could affect overall financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Global Medical Cannabis Revenue: Annual global medical cannabis net revenue is expected to increase year-over-year to between $269 million and $281 million, driven primarily by 10% to 15% growth in the global Medical Cannabis segment.
Plant Propagation Revenue: Plant propagation revenue is expected to perform in line with traditional seasonal trends as 65% to 75% of revenues are normally earned in the first half of a calendar year.
Consolidated Adjusted Gross Margins: Consolidated adjusted gross margins are expected to remain strong due to favorable sales mix from higher global medical cannabis revenue and operational efficiencies in manufacturing sites.
Annual Consolidated Adjusted EBITDA: Annual consolidated adjusted EBITDA is anticipated to increase year-over-year with an expected range of $52 million to $57 million, representing 5% to 10% annual growth.
German Market Expansion: Doubling production at the manufacturing site in Germany to facilitate yield improvements and operational efficiencies, preparing for further growth in Germany and adjacent regulated markets.
Australian Market Strategy: Shifting Australian sales mix towards core and premium products to improve margins and expand patient access through additional distribution agreements.
Poland Market Leadership: Maintaining #1 position in Poland through increased annual import limits, collaboration with regulatory authorities, and broadening product portfolio with new proprietary cultivars.
UK Market Strategy: Expanding distribution and clinic relationships through new partnerships to strengthen presence in premium and super-premium segments.
Canadian Consumer Cannabis Operations: Gradually scaling back Canadian consumer cannabis operations to focus on higher-margin global medical cannabis business, which is expected to improve adjusted EBITDA contributions after fiscal Q4.
At-the-Market Equity Program: Establishing a new at-the-market equity program to issue and sell up to USD 100 million of common shares for strategic purposes, including increased cultivation capacity and potential M&A.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the run rate for the select market exit in Canada, and will the company fully exit consumer cannabis in Canada?
A:The company is evaluating the run rate for the select market exit in Canada. Management stated that reallocating resources, particularly high-quality flower, to the international market will benefit financial results. They are flexible and continue to evaluate whether to fully exit consumer cannabis in Canada, prioritizing profitability and growth.
Q:How disruptive is the premiumization strategy in Australia, and what is the expected timeline for benefits?
A:Management stated that the premiumization strategy in Australia is not disruptive. The market is diverse, and there is growing interest in premium products. The strategy aligns with their global premium and core model and is accretive in terms of margins. No specific timeline for benefits was provided.
Q:What is the strategic decision behind exiting the Plant Propagation business, and when is the transaction expected to close?
A:The decision to exit the Plant Propagation business aligns with the company's focus on global medical cannabis, which is more profitable. The investment in plant propagation was no longer aligned with their strategy. The transaction involves divesting the majority share to existing shareholders, with some continued economic participation. No specific closing timeline was provided.
Q:What is the expected contribution of the Plant Propagation business to EBITDA for the full year and Q4?
A:Management is finalizing the closing conditions and financial implications. The Plant Propagation business will be treated as discontinued operations, and the focus will shift to global medical cannabis. No specific EBITDA contribution was provided.
Q:How is the company navigating regulatory pressures in Poland, and has anything changed since last quarter?
A:The company adapted quickly to regulatory changes in Poland by leveraging its strong system, product development, and distribution capabilities. They established connections with clinics to address restrictions on online consultations. Management emphasized agility and strong relationships with regulators.
Q:Are the year-to-date global medical cannabis revenue numbers comparable to the full-year guidance, and why is there an implied deceleration in Q4?
A:The full-year guidance includes total revenue, which encompasses the Bevo business. With the divestiture of Bevo, its results will be treated as discontinued operations. Management expects a strong Q4 but highlighted potential headwinds in some markets. They did not directly address the implied deceleration.
Q:Why is the adjusted gross margin in the wholesale business higher than in the consumer cannabis segment?
A:The wholesale business benefits from regulatory requirements and the unique availability of its products, leading to higher margins. The consumer cannabis segment faces tighter margins, which is consistent across the industry.
Q:What are the potential uses of funds raised through the ATM, and are there any specific M&A targets?
A:The funds will be used opportunistically, focusing on global medical cannabis. Potential areas include cultivation capacity, distribution, clinics, and other aspects of the medical cannabis business. No specific M&A targets were disclosed.
Q:What type of SG&A savings might result from exiting consumer cannabis in Canada?
A:Management is still evaluating the SG&A savings. They anticipate financial benefits and plan to reallocate inputs to higher-margin international markets. Specific savings were not disclosed.
Q:Are there any new international markets the company is considering entering?
A:The company is exploring new markets such as Switzerland, Austria, France, Ukraine, and Turkey. They prioritize markets with strong regulatory profiles and have a track record of entering and sustaining business in new markets.
Q:Will rescheduling cannabis in the U.S. allow the company to enter the U.S. market?
A:Rescheduling cannabis to Schedule III does not currently allow Canadian companies traded on NASDAQ to enter the U.S. market. However, it expands research opportunities and aligns with the company's focus on medical cannabis.
Q:What is the company's current supply chain structure, and what are their plans for acquisitions?
A:The majority of products sold internationally are produced in-house, with a focus on GMP-certified premium flower. The company is open to acquiring cultivation capacity, including indoor and greenhouse facilities, and is not limited to Canada. They emphasize the importance of GMP certification and high-quality production.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the implied deceleration in Q4 global medical cannabis revenue, providing only general comments about potential headwinds and focusing on full-year guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATM
Medical Cannabis
Plant Propagation
Propagation segment
action
advantage
cannabis market
cannabis sale
clinic relationship
commitment
company Aurora
consistency
consumer cannabis
contract labor
core premium
decrease
import
income cash
investment
leader cannabis
manufacturing site
market share
outlook
premium product
pressure
product market
program
propagation margin
purpose
quality standard
resource
review
sale mix
value product
ACB Transcript
Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript
Unknown2-4
The earnings call summary suggests a mix of positive and neutral aspects. Positive factors include strong financial performance and strategic focus on profitable segments like global medical cannabis. However, uncertainties such as the exit from plant propagation, lack of specific timelines, and unclear management responses regarding revenue deceleration create a balanced outlook. The Q&A section did not reveal significant risks but highlighted strategic shifts and market exploration. Overall, the sentiment appears neutral due to the balanced nature of positive growth strategies and uncertainties in execution and market conditions.
Aurora Cannabis Inc. (ACB:CA) Q2 2026 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed bag: strong growth in medical cannabis and plant propagation segments, but declining consumer cannabis revenue and increased SG&A expenses. The Q&A highlights structural advantages in international markets but reveals uncertainties in regulatory environments and cash flow challenges. Despite positive adjusted net income and margin improvements, negative free cash flow and unclear guidance on regulatory impacts temper optimism. Without market cap details, a neutral stance is prudent, reflecting balanced positive and negative factors.
Aurora Cannabis Inc. (ACB) Q1 2026 Earnings Call Transcript
Positive8-6
The earnings call reveals a strong financial performance with record medical cannabis revenue and improved margins. Despite lower consumer cannabis revenue, strategic focus on high-margin medical cannabis and international growth are promising. Positive cash flow and no cannabis business debt highlight financial health. The Q&A section reveals challenges in Europe but also demonstrates management's proactive strategies. While SG&A expenses are higher, they are partly one-time. Overall, the optimistic guidance for future EBITDA and market expansion suggests a positive sentiment, likely resulting in a stock price increase in the short term.
Aurora Cannabis Inc. (ACB) Q4 2025 Earnings Call Transcript
Positive6-18
The earnings call highlighted strong financial performance with a 34% revenue growth and a significant increase in adjusted EBITDA. Despite a temporary decline in Poland, management provided optimistic guidance, particularly with international market expansion plans. The Q&A revealed confidence in overcoming competitive challenges and maintaining supply levels. Although management was vague on some specifics, the overall sentiment remained positive, especially with strong margins and no debt. Given these factors, a positive stock price movement is anticipated over the next two weeks.
ACB Slides
ACB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
